文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

外科重症监护病房脓毒症后慢性危重症的临床结局基准与免疫分解代谢表型

Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论外科ICU脓毒症患者中49%发展为慢性危重症,其6个月死亡率37%远高于快速恢复者的2%,并呈现持续炎症、免疫抑制和分解代谢的免疫分解代谢表型。

这项为期3年的前瞻性观察性队列研究(NCT02276417)纳入145例外科ICU脓毒症患者,评估慢性危重症(CCI,定义为ICU资源利用≥14天并持续器官功能障碍)的发生率及临床结局。145例中19例(13%)住院期间死亡,71例(49%)发展为CCI。CCI患者年龄更大(平均63±15岁 vs 58±13岁,p=0.006),更常转至长期急性护理机构(32% vs 3%,p<0.0001),6个月死亡率显著高于快速恢复(RAP)组(37% vs 2%,p<0.01)。多因素logistic回归显示延迟发病脓毒症(入院>48小时后,OR 10.93,95%CI 4.15-28.82)、院间转运(OR 3.58,95%CI 1.43-8.96)、血管活性药依赖性脓毒性休克(OR 3.75,95%CI 1.47-9.54)和72小时SOFA评分≥5分(OR 5.03,95%CI 2.00-12.62)是CCI的独立危险因素。CCI患者炎症细胞因子(IL-6、IL-8、IL-10)升高更明显,生物标志物谱符合持续免疫抑制(绝对淋巴细胞计数和可溶性程序性死亡配体1)和分解代谢(血浆胰岛素样生长因子结合蛋白3和尿3-甲基组氨酸排泄)。

要点

  • 外科ICU脓毒症患者中49%(71/145)发展为慢性危重症(CCI,ICU资源利用≥14天并持续器官功能障碍),住院死亡率13%(19/145)。
  • CCI患者6个月死亡率37%,快速恢复(RAP)患者仅2%(p<0.01);CCI患者更常转至长期急性护理机构(32% vs 3%,p<0.0001)。
  • 延迟发病脓毒症(入院>48小时后)是CCI最强独立危险因素(OR 10.93,95%CI 4.15-28.82),其次为72小时SOFA评分≥5分(OR 5.03,95%CI 2.00-12.62)。
  • 院间转运(OR 3.58,95%CI 1.43-8.96)和血管活性药依赖性脓毒性休克(OR 3.75,95%CI 1.47-9.54)也是CCI独立危险因素。
  • CCI患者IL-6、IL-8、IL-10升高更明显,绝对淋巴细胞计数和可溶性PD-L1符合持续免疫抑制,IGFBP3和尿3-甲基组氨酸符合分解代谢。

适用人群与场景

  • 外科重症监护病房脓毒症患者,前瞻性观察性队列研究纳入145例。
  • CCI定义为ICU资源利用≥14天并持续器官功能障碍。
  • 快速恢复(RAP)作为对照人群。

诊断标准与关键阈值

  • 慢性危重症(CCI)定义:ICU资源利用≥14天并持续器官功能障碍。
  • 72小时序贯器官衰竭评估(SOFA)评分≥5分是CCI独立危险因素(OR 5.03,95%CI 2.00-12.62)。
  • 延迟发病脓毒症定义为入院>48小时后发生脓毒症(OR 10.93,95%CI 4.15-28.82)。

红旗征与不能漏的情况

  • 入院>48小时后发生的延迟发病脓毒症,CCI风险显著升高(OR 10.93,95%CI 4.15-28.82)。
  • 院间转运患者CCI风险升高(OR 3.58,95%CI 1.43-8.96)。
  • 血管活性药依赖性脓毒性休克患者CCI风险升高(OR 3.75,95%CI 1.47-9.54)。
  • 72小时SOFA评分≥5分提示CCI风险升高(OR 5.03,95%CI 2.00-12.62)。

研究设计与关键结果

  • 研究类型:为期3年的前瞻性观察性队列研究(NCT02276417),纳入145例外科ICU脓毒症患者。
  • 145例中19例(13%)住院期间死亡,71例(49%)发展为CCI。
  • CCI患者年龄更大(平均63±15岁 vs 58±13岁,p=0.006)。
  • CCI患者更常转至长期急性护理机构(32% vs 3%,p<0.0001),RAP患者更常出院回家或转至康复机构。
  • CCI患者6个月死亡率显著高于RAP组(37% vs 2%,p<0.01)。
  • 多因素logistic回归:延迟发病脓毒症(>48小时,OR 10.93,95%CI 4.15-28.82)、院间转运(OR 3.58,95%CI 1.43-8.96)、血管活性药依赖性脓毒性休克(OR 3.75,95%CI 1.47-9.54)、72小时SOFA评分≥5分(OR 5.03,95%CI 2.00-12.62)为CCI独立危险因素。
  • CCI患者炎症细胞因子IL-6、IL-8、IL-10升高更明显,绝对淋巴细胞计数和可溶性程序性死亡配体1符合持续免疫抑制,血浆胰岛素样生长因子结合蛋白3和尿3-甲基组氨酸排泄符合分解代谢。

证据类型、等级与局限

  • 证据类型:前瞻性观察性队列研究(预后研究),证据等级Level II。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 外科ICU脓毒症患者中约半数发展为CCI,住院期间应关注延迟发病脓毒症、院间转运、血管活性药依赖性脓毒性休克及72小时SOFA评分≥5分等高危因素。
  • CCI患者6个月死亡率37%,出院去向常为长期急性护理机构,与快速恢复者不同,出院规划需考虑长期护理需求。
  • CCI患者呈现持续炎症、免疫抑制和分解代谢的免疫分解代谢表型,生物标志物(IL-6、IL-8、IL-10、绝对淋巴细胞计数、可溶性PD-L1、IGFBP3、尿3-甲基组氨酸)可能有助于识别该表型。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A growing number of patients survive sepsis but remain chronically critically ill. We sought to define clinical outcomes and incidence of chronic critical illness (CCI) after sepsis and to determine whether selected biomarkers of inflammation, immunosuppression, and catabolism differ between these patients and those that rapidly recover (RAP).

METHODS: This 3-year prospective observational cohort study (NCT02276417) evaluated 145 surgical intensive care unit patients with sepsis for the development of CCI (≥14 days of intensive care unit resource utilization with persistent organ dysfunction). Patient clinical demographics, outcomes, and serial serum/urine samples were collected for plasma protein and urinary metabolite analyses.

RESULTS: Of 145 sepsis patients enrolled, 19 (13%) died during their hospitalization and 71 (49%) developed CCI. The CCI patients were significantly older (mean, 63 ± 15 vs. 58 ± 13 years, p = 0.006) and more likely to be discharged to long-term acute care facilities (32% vs. 3%, p < 0.0001), whereas those with RAP were more often discharged to home or a rehabilitation facility. Six-month mortality was significantly higher in CCI as compared with RAP cohort (37% vs. 2%; p < 0.01). Multivariate logistic regression modeling revealed delayed onset sepsis (>48 hours after admission; odds ratio [OR], 10.93; 95% confidence interval [CI], 4.15-28.82]), interfacility transfer (OR, 3.58; 95% CI, 1.43-8.96), vasopressor-dependent septic shock (OR, 3.75; 95% CI, 1.47-9.54), and Sequential Organ Failure Assessment score of 5 or greater at 72 hours (OR, 5.03; 95% CI, 2.00-12.62) as independent risk factors for the development of CCI. The CCI patients also demonstrated greater elevations in inflammatory cytokines (IL-6, IL-8, IL-10), and biomarker profiles are consistent with persistent immunosuppression (absolute lymphocyte count and soluble programmed death ligand 1) and catabolism (plasma insulin-like growth factor binding protein 3 and urinary 3-methylhistidine excretion).

CONCLUSION: The development of CCI has become the predominant clinical trajectory in critically ill surgical patients with sepsis. These patients exhibit biomarker profiles consistent with an immunocatabolic phenotype of persistent inflammation, immunosuppression, and catabolism.

LEVEL OF EVIDENCE: Prognostic, level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Stortz JA, Mira JC, Raymond SL, et al. Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. J Trauma Acute Care Surg. 2018. PMID: 29251709. doi:10.1097/TA.0000000000001758

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。